Guggenheim Reiterates "Buy" Rating for UroGen Pharma (NASDAQ:URGN)

UroGen Pharma (NASDAQ:URGN - Get Free Report)'s stock had its "buy" rating reiterated by Guggenheim in a report released on Tuesday,Benzinga reports.

Several other research analysts have also recently commented on URGN. LADENBURG THALM/SH SH assumed coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They issued a "buy" rating and a $31.00 target price for the company. The Goldman Sachs Group decreased their price target on UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. Scotiabank assumed coverage on shares of UroGen Pharma in a research note on Wednesday, April 16th. They set a "sector outperform" rating and a $23.00 target price for the company. HC Wainwright reiterated a "buy" rating and issued a $55.00 price target on shares of UroGen Pharma in a research report on Monday. Finally, D. Boral Capital reissued a "buy" rating and issued a $25.00 target price on shares of UroGen Pharma in a research report on Monday. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $32.86.

UroGen Pharma Stock Performance

Shares of NASDAQ:URGN traded down $0.00 during trading on Tuesday, hitting $11.26. 145,277 shares of the company traded hands, compared to its average volume of 525,237. The stock has a market capitalization of $518.97 million, a price-to-earnings ratio of -3.56 and a beta of 0.80. UroGen Pharma has a one year low of $8.94 and a one year high of $20.70. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The business's fifty day moving average is $10.44 and its 200-day moving average is $11.08.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its earnings results on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). The business had revenue of $24.57 million during the quarter, compared to the consensus estimate of $25.25 million. As a group, equities analysts predict that UroGen Pharma will post -3.12 earnings per share for the current fiscal year.

Insider Activity

In related news, General Counsel Jason Drew Smith sold 7,379 shares of UroGen Pharma stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $82,202.06. Following the transaction, the general counsel now owns 26,468 shares in the company, valued at $294,853.52. This trade represents a 21.80 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Mark Schoenberg sold 4,551 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the sale, the insider now directly owns 145,666 shares in the company, valued at $1,622,719.24. This trade represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by insiders.

Institutional Trading of UroGen Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Barclays PLC grew its position in UroGen Pharma by 409.3% during the third quarter. Barclays PLC now owns 59,778 shares of the company's stock worth $759,000 after buying an additional 48,040 shares in the last quarter. Geode Capital Management LLC increased its position in shares of UroGen Pharma by 8.1% during the third quarter. Geode Capital Management LLC now owns 455,637 shares of the company's stock valued at $5,787,000 after purchasing an additional 34,248 shares during the period. Tidal Investments LLC raised its stake in shares of UroGen Pharma by 19.1% in the third quarter. Tidal Investments LLC now owns 37,595 shares of the company's stock valued at $477,000 after purchasing an additional 6,030 shares in the last quarter. JPMorgan Chase & Co. lifted its position in UroGen Pharma by 263.1% in the third quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company's stock worth $864,000 after purchasing an additional 49,318 shares during the period. Finally, SG Americas Securities LLC boosted its stake in UroGen Pharma by 44.1% during the fourth quarter. SG Americas Securities LLC now owns 20,269 shares of the company's stock worth $216,000 after buying an additional 6,207 shares in the last quarter. 91.29% of the stock is currently owned by institutional investors and hedge funds.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.